CAR-T Cell Therapy Market By Targeted Antigen (CD 19, Pipeline Therapy Analysis), By Indication (Non-Hodgkin’s Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

The CAR-T cell therapy market was valued at US$ 72.0 Mn in 2017 and projected to exhibit double digit compound annual growth rate (CAGR) of 51.1% during the forecast period from 2018 to 2026. Scientist have encountered the biggest challenge in the treatment of cancer is that the cancer cells with the disease progression usually become invisible to the body’s defense mechanism. Immunotherapy is the future in the treatment of cancer where the immune cells are genetically engineered in order to recognize the biomarkers of cancerous cells, target them and kill them. CAR-T cells therapy do not kill the normal healthy cells and has proven effective in relapsed cancer treatment. 

The CAR-T cell therapy market is driven by factors such as rising prevalence of cancer, growing research in the immune-oncology, and massive funding from government health institution and pharma giants in CAR-T cell therapy development. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. However, advances in the cell therapy and gene therapy has have rendered the development of oncology treatment by body’s own immune system. The FDA approved CAR-T cell therapy are Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. Whereas, there are more than 2,000 candidates in the clinical trials for different cancer indications.

Market Synopsis

Growing Research and Development of CAR-T to Drive the Market Growth

CD 19 antigens are currently studied extensively to prove its efficacy in the treatment of acute lymphoblastic leukemia. Rising prevalence of acute lymphoblastic leukemia in children and adults has buttressed the dominance of CD 19 antigens to be utilized for cancer therapy. Yescarta (axicabtagene ciloleucel), and Kymriah (tisagenlecleucel) are the two approved CD19 therapies and the only CAR-T cell therapies currently approved in the market. CD 22 and CD 30 antigens are being studied diligently in the preclinical trials with promising results for the treatment of B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma respectively.

Rising Prevalence of Blood Cancers to Augment the Growth of CAR-T Cell Therapy Market

The non-Hodgkin’s lymphoma segment dominated the market in 2017 owing to a surge in the number of NHL cases coupled with the higher adoption of YESCARTA (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel, formerly CTL019) around the world. CAR T cell therapy products are currently indicated in non-Hodgkin’s lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia only. However, clinical trials of some CAR T cell therapy drugs being studied (under study) for the treatment of multiple myeloma, acute myeloid leukemia, melanoma, glioblastomas, myelodysplastic syndromes (MDS), and cancer of pancreatitis, prostate, bladder, esophagus, stomach, liver, lung, kidney, & cervix. Thus, proliferating application of CAR-T in various indication would further boost the market during the forecast period.

Increasing Adoption of CAR-T Cell Therapy in North America will Drive Swift Growth during the Forecast Period

In 2017, North America demonstrates supremacy in the global CAR-T cell therapy market owing to the exclusive availability of the two approved products Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.). Developed healthcare infrastructure, high accessibility to advanced therapies, rise in healthcare expenditure, incessant investment in R&D activities, and presence of established market leaders further catalyzes the overall market growth in this region. With Medicare constantly working on structuring suitable reimbursement policies for dynamically priced CAR-T cell therapies, the demand for it is projected to increase during the forecast period. In Asia Pacific, the market entry of Kymriah expected by end of 2018 in Japan. The extensive pipeline portfolio for CAR-T cell therapy in China and the continuous growing cancer prevalence in Asia Pacific regions predominantly contribute to the maximum growth.

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

CAR-T cell therapy market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on antigen type, indication and geography.

By Antigen Type (2016–2026; US$ Mn)

• CD 19
• Pipeline Analysis (Qualitative Analysis)
  
  • CD 20
  • CD 22
  • CD 30
  • CD 33
  • GD 2
  • HER 2
  • MESO
  • EGFRvIII
  •  

By Indication (2016–2026; US$ Mn)

• Non-Hodgkin’s Lymphoma
• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia
•  

Geography Segment (2016–2026; US$ Mn)

• North America 
  
  • U.S.
  • Canada
• Europe 
  
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific (APAC)
  
  • China
  • Japan
  • Rest of APAC
• Latin America (LATAM)
  
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa (MEA)
  
  • GCC
  • Rest of Middle East and Africa
  •  

Market is studied in order to understand the current and future market trends in the CAR-T cell therapy market. The market is estimated by providing the compounded annual growth rate (CAGR) and data forecast from 2018 to 2026. Strategic acquisition, merger and collaboration among the key players for developing innovative product pipeline mentioned in the business strategy section. The key players currently engaged in the CAR-T cell therapy market are Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Juno Therapeutics, Cellectis, Eureka Therapeutics, Kite Pharma, Sorrento Therapeutics and Novartis AG, Gilead Sciences among others.